Symbols

XGN

Exagen·NASDAQ

--(--)

XGN fundamentals

XGN Q4 2025 Earnings

Exagen (XGN) released its earnings on Mar 10, 2026: revenue was 16.63M (YoY +21.79%), beat estimates; EPS was -0.2 (YoY 0.00%), missed estimates.

Revenue / YoY

16.63M

+21.79%

EPS / YoY

-0.2

0.00%

Report date

Mar 10, 2026

XGN Earnings Call Summary for Q4,2025

Revenue Growth: 2025 revenue up 20% to $66.6 million, driven by 11% volume growth and 7% ASP increase.
ASP Recovery: Q4 2025 ASP ~$430, expected to trend higher in 2026 with new biomarker contributions.
Pipeline Momentum: Myositis biomarkers targeting 2027 launch, with ACR advocacy driving commercial access.
Financial Discipline: 2026 guidance of $70M-$73M revenue reflects balanced growth and margin optimization.
Cash Position: $32 million cash at year-end, providing runway for 2026 initiatives.

Earnings

EPS

Revenue

Revenue & Expenses

XGN has released its 2025 Q4 earnings report, with revenue of 16.63M, reflecting a YoY change of 21.79%, and net profit of -4.67M, showing a YoY change of -24.25%. The Sankey diagram below clearly presents XGN's revenue sources and cost distribution.

Key Indicators

Exagen (XGN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Exagen (XGN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Exagen (XGN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Exagen (XGN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown